2021's NDA list in­cludes some ex­tra­or­di­nary ac­com­plish­ments in year #2 of the pan­dem­ic

All the big R&D trends are on dis­play in this new list of drug ap­provals for 2021. Plus one.

Add up every­thing OK’d from CDER and CBER, and you have 60 new drug ap­provals for last year, top­ping the 59 in 2020. That’s a close sec­ond to the 64 OKs that came out of the FDA in 2018. The dark days of the ear­ly 2000s are a dis­tant mem­o­ry now, with a host of hun­gry up­starts promis­ing to make their own en­tries one day as Big Phar­mas dou­ble down on in­no­va­tion.

There’s the new list of small biotechs that nailed down their first drug ap­provals, ex­press­ing noth­ing but ea­ger­ness to get out there and start mar­ket­ing — some­thing they all have much to learn about. Not all of these drugs are tip­ping the scales on the com­mer­cial side, but that doesn’t mean they aren’t im­por­tant to the small or­phan pop­u­la­tions that set this trend in mo­tion more than a decade ago.

In the mean­time the list of small­er play­ers mak­ing the leap now in­clude biotechs like Apel­lis and ADC Ther­a­peu­tics. Kad­mon hit, then sold to Sanofi. Can they per­form like the an­a­lysts have promised? Hopes and fore­casts dur­ing de­vel­op­ment are one thing, but as Bio­gen ex­ecs can tell you, sales is an un­for­giv­ing, hard-num­bers game.

There are the late ar­rivals in the win col­umn, of­ten show­ing up at the reg­u­la­to­ry fin­ish line well past sched­ule, some­times cuffed and bruised by CMC is­sues that con­tin­ue to plague the field. The FDA has shown time and again that it isn’t in a for­giv­ing mood over sus­pect man­u­fac­tur­ing prob­lems. That trend looks em­bed­ded in­to the fab­ric of the drug ap­proval process, for big and small com­pa­nies alike.

No­var­tis dealt with that, be­fore get­ting their ap­proval of Leqvio (in­clisir­an) and will now put its colos­sal shoul­der be­hind the com­mer­cial wheel in the LDL mar­ket.

The ma­jor play­ers, of course, tend­ed to dom­i­nate the list of po­ten­tial block­busters. That’s an­oth­er in­dus­try tra­di­tion. So As­traZeneca and Am­gen made no­table con­tri­bu­tions to the list, for break­through asth­ma as well as im­pres­sive can­cer drugs. Ab­b­Vie made its mark with mi­graines, which is see­ing a new wave of ther­a­pies en­ter the mar­ket.

As al­ways, sheer grit counts for much of the suc­cess. SeaGen’s suc­cess with next-gen AD­Cs is an ex­am­ple of that. As­traZeneca’s R&D staff al­most nev­er gives up, but just keeps bat­tling ahead, chang­ing tri­al de­signs, per­sist­ing. In that sense, fi­nal­ly fin­ish­ing its world head­quar­ters in Cam­bridge, UK in 2021 was a fit­ting sym­bol for the com­pa­ny’s stub­born­ness. They may not wow you with speed every time, but they get to the reg­u­la­to­ry goal posts.

But amid all the hard work and en­durance, let’s not over­look the year’s tri­umphs, topped by Al­bert Bourla’s Pfiz­er. Faced with a pan­dem­ic, Pfiz­er took its part­ner­ship with BioN­Tech to leg­end sta­tus. Its mR­NA vac­cine pro­vid­ed an in­stant burst of sales worth tens of bil­lions of dol­lars. They got there first, break­ing de­vel­op­ment and reg­u­la­to­ry bar­ri­ers, and set up a fran­chise that will help trans­form the multi­na­tion­al for the decade ahead. And let’s not for­get that they did it in a year in which they brought through Pre­vnar 20, a next-gen ap­proach that is ex­pect­ed to safe­guard one of its biggest fran­chis­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER